<?xml version="1.0" encoding="utf-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
>

<channel rdf:about="http://www.biochemj.org">
<title>BJ Gene Immediate Publications</title>
<link>http://www.biochemj.org</link>
<description>Biochemical Journal RSS feed -- BJ Gene Immediate Publications</description>
<prism:issn>0264-6021</prism:issn>
<prism:eIssn>1470-8728</prism:eIssn>
<prism:publicationName>Biochemical Journal</prism:publicationName>
<items>
 <rdf:Seq>
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20130432" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121126" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121598" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121699" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20130049" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121908" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121742" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20130012" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121277" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20130154" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121666" />
 </rdf:Seq>
</items>
<image rdf:resource="http://www.biochemj.org/images/BJ_Name.gif" />
</channel>

<image rdf:about="http://www.biochemj.org/images/BJ_Name.gif">
<title>Biochemical Journal</title>
<url>http://www.biochemj.org/images/BJ_Name.gif</url>
<link>http://www.biochemj.org</link>
</image>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20130432">
	<title><![CDATA[Minimal Functional Domains of Paralogues hnRNP L and hnRNP LL Exhibit Mechanistic Differences in Exonic Splicing Repression]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20130432</link>
	<description><![CDATA[Understanding functional distinctions between related splicing regulatory proteins is critical to deciphering tissue-specific control of alternative splicing. The hnRNP L and hnRNP LL proteins are paralogues that have overlapping but distinct expression patterns and functional consequences. These two proteins share high sequence similarity in their RNA-recognition motifs (RRMs), but diverge in regions outside of the RRMs. In this study, we use an MS2-tethering assay to delineate the minimal domains of hnRNP L and hnRNP LL which are required for repressing exon inclusion. We demonstrate that for both proteins, regions outside the RRMs &#x2013; the N-terminal region, and a linker sequence between RRMs 2 and 3 &#x2013; are necessary for exon repression, but are only sufficient for repression in the case of hnRNP LL. In addition, both proteins require at least one RRM for maximal repression. Notably, we demonstrate that the region encompassing RRMs 1-2 of hnRNP LL imparts a second silencing activity not observed for hnRNP L. This additional functional component of hnRNP LL is consistent with the fact that the full length hnRNP LL has greater silencing activity than hnRNP L. Thus, our data provide important insight into the functional and mechanistic variations that can exist between two highly related hnRNP proteins.]]></description>
	<dc:creator>G Shankarling, K W Lynch</dc:creator>
	<dc:date>2013-05-07T11:21:40Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20130432</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2013-05-07</prism:publicationDate>
	<prism:section>BJ Gene</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121126">
	<title><![CDATA[MondoA senses adenine nucleotides: transcriptional induction of thioredoxin-interacting protein]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121126</link>
	<description><![CDATA[The MondoA:Mlx transcription complex plays a pivotal role in glucose homeostasis by activating target gene expression in response to glucose-6-phosphate (G6P), the first reaction intermediate in glycolysis. Thioredoxin-interacting protein (TXNIP) is a direct and glucose-responsive target of MondoA that triggers a negative feedback loop by restricting glucose uptake when G6P levels increase. We show here that TXNIP expression is also activated by 5-aminoimidazole-4-carboxamide ribofuranoside (AICAR) and adenosine. Using pharmacologic inhibitors and genetic knockdowns of purine metabolic enzymes, we establish that TXNIP induction by AICAR and adenosine requires their cellular uptake and metabolism to adenine nucleotides. AICAR induction of TXNIP depended on MondoA but was independent of AMPK activation and calcium. Our findings have two important implications. First, in addition to activating AMPK, AICAR may have AMPK-independent effects on gene expression by regulating MondoA:Mlx activity following its flux into the adenine nucleotide pool. Second, MondoA:Mlx complexes sense elevated levels of G6P and adenine nucleotides to trigger a TXNIP-dependent feedback inhibition of glycolysis. We propose that this mechanism serves as checkpoint to restore metabolic homeostasis.]]></description>
	<dc:creator>K Han, D E Ayer</dc:creator>
	<dc:date>2013-05-01T09:39:43Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20121126</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2013-05-01</prism:publicationDate>
	<prism:section>BJ Metabolism</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121598">
	<title><![CDATA[Lipin1 regulates PPAR{gamma} transcriptional activity]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121598</link>
	<description><![CDATA[Peroxisome proliferator-activated receptor-&#x03B3; (PPAR&#x03B3;) is a master transcription factor involved in adipogenesis through regulating adipocyte-specific gene expression. Recently, lipin1 is known to act as a key factor for the adipocyte maturation and maintenance with modulating C/EBP&#x03B1; and PPAR&#x03B3; network. However, the precise mechanism by which lipin1 affects transcriptional activity of PPAR&#x03B3; is largely unknown. The present study revealed that lipin1 activates PPAR&#x03B3; by releasing corepressors, nuclear receptor corepressor 1 (NcoR1) and silencing mediator of retinoid and thyroid hormone receptors (SMRT), from PPAR&#x03B3; in the absence of ligand, rosiglitazone. Also, we identified a novel lipin1 transcriptional activation domain (TAD), between residues 217 to 399, which is critical for the activation of PPAR&#x03B3; but not PPAR&#x03B1;. Furthermore, this TAD is unique to lipin1 since this region does not show any homology with other lipin isoforms; lipin2 and lipin3. Activity of the lipin1 TAD is enhanced by p300 and SRC-1, but not by PCAF and PGC-1&#x03B1;. The physical interaction between lipin1 and PPAR&#x03B3; occurs at the lipin1 C-terminal region from residues 825 to 926, where the VXXLL motif at residue 885 is critical for binding with and the activation of PPAR&#x03B3;. The action of lipin1 as a coactivator of PPAR&#x03B3; enhanced the adipocyte differentiation, where TAD and VXXLL motif played the critical role but the catalytic activity of lipin1 was not directly involved. Collectively, these data suggest that lipin1 functions as a key regulator of PPAR&#x03B3; activity through its ability to release corepressors and recruit coactivators via a different mechanism compared with PPAR&#x03B1; activation.]]></description>
	<dc:creator>H Kim, E Bae, D Jeong, M Kim, W Jin, S Park, G Han, G Carman, E Koh, K Kim</dc:creator>
	<dc:date>2013-04-30T09:24:37Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20121598</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2013-04-30</prism:publicationDate>
	<prism:section>BJ Metabolism</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121699">
	<title><![CDATA[Mechanistic insights into small RNA recognition and modification by the HEN1 methyltransferase]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121699</link>
	<description><![CDATA[The HEN1 methyltransferase from <i>Arabidopsis thaliana</i> modifies the 3'-terminal nucleotides of small regulatory RNAs. Although it is one of the best characterized members of the 2&#x2019;-O-methyltransferase family, many aspects of its interactions with the cofactor and substrate RNA remained unresolved. To better understand substrate interactions and contributions of individual steps during HEN1 catalysis, we studied binding and methylation kinetics using series of unmethylated, hemimethylated and doubly methylated miRNA and siRNA substrates. Our studies indicate that HEN1 specifically binds double-stranded unmethylated or hemimethylated miR173/miR173* substrates with sub-nanomolar affinity in a cofactor-dependent manner. Kinetic studies under single turnover and pre-steady state conditions in combination with isotope partitioning analysis showed that the binary HEN1&#x2022;miRNA/miRNA* complex is catalytically competent, however successive methylation of the two strands in a RNA duplex occurs in a non-processive (distributive) manner. We also find that the observed moderate methylation strand preference is largely exerted at the RNA binding step and is fairly independent of the nature of the 3&#x2019;-terminal nucleobase but shows some dependency on proximal nucleotide mispairs. Our results thus provide novel insights into the mechanism of RNA recognition and modification by a representative small RNA 2&#x2019;-O-methyltransferase.]]></description>
	<dc:creator>A Plotnikova, S Baranausk&#x0117;, A Osipenko, S Klima&#x0161;auskas, G Vilkaitis</dc:creator>
	<dc:date>2013-04-29T10:11:32Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20121699</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2013-04-29</prism:publicationDate>
	<prism:section>BJ Gene</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20130049">
	<title><![CDATA[Decreased translation of Dio3 mRNA is associated with drug-induced hepatotoxicity.]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20130049</link>
	<description><![CDATA[Recent work has demonstrated the importance of post-transcriptional gene regulation in toxic responses. Here we used two rat models to investigate mRNA translation in the liver following xenobiotic-induced toxicity. By combining polysome profiling with genomic methodologies we were able to assess global changes in hepatic mRNA translation. Iodothyronine deiodinase, type III (<i>Dio3</i>) was identified as a gene that exhibited specific translational repression and had a functional role in a number of relevant canonical pathways. Western blot analysis indicated that this repression led to reduced <i>Dio3</i> protein (D3) levels, enhanced over time and with increased dose. Using Northern blotting techniques and quantitative RT-PCR we further confirmed that there was no reduction in <i>Dio3</i> mRNA, suggesting that translational repression of <i>Dio3</i> is an important determinant of the reduced D3 protein expression following liver damage. Finally, we show that drug-induced hepatotoxicity appears to cause localised disruptions in thyroid hormone levels in the liver and plasma. We suggest that this leads to reduced translation of <i>Dio3</i> mRNA, which results in decreased D3 production. It may, therefore, be possible that this is an important mechanism by which the liver can, upon early signs of damage, act rapidly to maintain its own energy equilibrium, thereby avoiding global disruption of the hypothalamic-pituitary-thyroid axis.]]></description>
	<dc:creator>K M Dudek, L Suter, V M Darras, E L Marczylo, T W Gant</dc:creator>
	<dc:date>2013-04-16T09:56:56Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20130049</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2013-04-16</prism:publicationDate>
	<prism:section>BJ Gene</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121908">
	<title><![CDATA[A Covalent Protein-DNA 5'-Product Adduct is Generated Following AP Lyase Activity of Human AlkB Homolog 1 (ALKBH1)]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121908</link>
	<description><![CDATA[ALKBH1 is a mammalian AlkB homolog that possesses abasic site (AP) lyase activity. The AP lyase reaction is catalyzed by imine formation with an active site Lys, and a covalent intermediate can be trapped in the presence of NaBH<sub>4</sub>. Surprisingly, ALKBH1 also forms a stable protein-DNA adduct in the absence of a reducing agent. Experiments with different substrates demonstrated that the protein covalently binds to the 5' DNA product; i.e., the fragment containing an &#x03B1;,&#x03B2;-unsaturated aldehyde. The amino terminal domain of ALKBH1 was identified as the main site of linkage with DNA. By contrast, mutagenesis studies suggest that the primary catalytic residue forming the imine linkage is Lys133, with Lys154 and other Lys residues in this region serving in opportunistic roles. These findings confirm the classification of ALKBH1 as an AP lyase, identify the primary and a secondary Lys involved in the lyase reaction, and demonstrate the protein forms a covalent adduct with the 5' DNA product. We propose two plausible chemical mechanisms to account for the covalent attachment.]]></description>
	<dc:creator>T A. M&#x00FC;ller, M M. Andrzejak, R P. Hausinger</dc:creator>
	<dc:date>2013-04-12T11:11:44Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20121908</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2013-04-12</prism:publicationDate>
	<prism:section>BJ Gene</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121742">
	<title><![CDATA[Comprehensive Characterization and Optimization of Leucine Rich Repeat Kinase 2 (LRRK2) Monoclonal Antibodies]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121742</link>
	<description><![CDATA[Missense mutations in <i>leucine-rich repeat kinase 2</i> (<i>LRRK2</i>) are a major cause of Parkinson&#x2019;s disease (PD). Several antibodies against LRRK2 have been developed, but results using these polyclonal antibodies have varied widely leading to conflicting conclusions. To address this challenge, The Michael J. Fox Foundation for Parkinson&#x2019;s Research generated a number of monoclonal antibodies targeting epitopes across the LRRK2 protein. Herein, we report optimized protocols and results for ten monoclonal antibodies for immunoblotting, immunohistochemistry, immunoprecipitation, and kinase activity assays, in rat, mouse, and human brain tissue. Several efficacious antibodies were identified, but results demonstrate that the mouse monoclonal N241A/34 is suitable for most applications, with the best overall rabbit monoclonal antibody being c41-2. These antibodies produced a dominant band of the expected size via immunoblotting and a lack of labeling in tissue derived from <i>LRRK2 </i>knockout animals under optimized conditions. A significant proportion of LRRK2 protein localizes to insoluble fractions and no evidence of truncated LRRK2 protein was detected in any fraction from rodent or human tissues. An assay was developed for the robust detection of LRRK2 kinase activity directly from frozen mouse and human brain tissue, but precipitous declines in activity were observed that corresponded to increasing post-mortem intervals and processing times. Finally, we demonstrate the highest levels of brain-localized LRRK2 in the striatum, but note differential expression patterns between rat and mouse in both striatum and cortex. LRRK2 monoclonal antibodies that are unlimited in availability together with the proposed standardized protocols should aid in the definition of LRRK2 function in both health and disease.]]></description>
	<dc:creator>P Davies, K M Hinkle, N N Sukar, B Sepulveda, R Mesias, G Serrano, D R Alessi, T G Beach, D L Benson, C L White III, R M Cowell, S S Das, A B West, H L Melrose</dc:creator>
	<dc:date>2013-04-05T15:31:38Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20121742</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2013-04-05</prism:publicationDate>
	<prism:section>BJ Disease</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20130012">
	<title><![CDATA[Structural and Functional Interactions of the Prostate Cancer Suppressor NKX3.1 with Topoisomerase I]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20130012</link>
	<description><![CDATA[NKX3.1 is a prostate tumor suppressor protein that binds to topoisomerase I and enhances its DNA cleavage activity. We show that the NKX3.1 homeodomain binds to a region of topoisomerase I spanning the junction between core and linker domains. NKX3.1 activated N-terminal truncated topoisomerase I (Topo70) in vitro. In contrast, NKX3.1 interacts with the enzyme reconstituted from peptide fragments of core domain and linker-active site domains, but inhibits the DNA unwinding activity of the reconstituted enzyme in vitro. The effect of NKX3.1 on both Topo70 and the reconstituted enzyme was seen in the presence and absence of camptothecin. Neither NKX3.1 nor camptothecin had an effect on the interaction of the other with topoisomerase I. Therefore the interactions of NKX3.1 and camptothecin with the linker domain of topoisomerase I are mutually exclusive. However, in cells the effect of NKX3.1 on topoisomerase binding to DNA sensitized cells to cellular toxicity and induction of apoptosis by low dose CPT. Lastly, topoisomerase I is important for the effect of NKX3.1 on cell survival after DNA damage as topoisomerase knockdown blocked the effect of NKX3.1 on clonogenicity after DNA damage. Therefore, NKX3.1 and topoisomerase I interact in vitro and in cells to affect CPT sensitivity and DNA repair functions of NKX3.1.]]></description>
	<dc:creator>L Song, C Bowen, E P Gelmann</dc:creator>
	<dc:date>2013-04-05T10:01:10Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20130012</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2013-04-05</prism:publicationDate>
	<prism:section>BJ Biomolecules</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121277">
	<title><![CDATA[Role of the unstructured N-terminal domain of the human Apurinic/Apyrimidinic Endonuclease 1 (hAPE1) in the modulation of its interaction with nucleic acids and Nucleophosmin (NPM1)]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121277</link>
	<description><![CDATA[The human Apurinic/apyrimidinic endonuclease 1 (hAPE1) is an essential enzyme, being the main abasic endonuclease in higher eukaryotes. However, many evidences show that hAPE1 can directly bind specific gene promoters, thus modulating their transcriptional activity, even in the absence of specific DNA damage. Recent findings, moreover, suggest a role for hAPE1 in RNA processing, which is modulated by the interaction with Nucleophosmin (NPM1). Independent domains account for many activities of hAPE1; however, while the endonuclease and the redox-active portions of the protein are well characterized, a better understanding of the role of the unstructured N-terminal region is needed. Here, we characterized the requirements for the interaction of hAPE1 with NPM1 and with undamaged nucleic acids. We show that DNA/RNA secondary structure has an impact on hAPE1 binding in the absence of damage. Biochemical studies, using the isolated N-terminal region of the protein, reveal that the hAPE1 N-terminal domain represents an evolutionary gain of function, since its composition affects the protein&#x2019;s stability and ability to interact with both nucleic acids and NPM1. Although required, however, this region is not sufficient, <i>per se</i>, to stably interact with DNA or NPM1.]]></description>
	<dc:creator>M Poletto, C Vascotto, P L. Scognamiglio, L Lirussi, D Marasco, G Tell</dc:creator>
	<dc:date>2013-04-02T09:38:44Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20121277</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2013-04-02</prism:publicationDate>
	<prism:section>BJ Gene</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20130154">
	<title><![CDATA[GlgS, previously described as a glycogen synthesis control protein, negatively regulates motility and biofilm formation in Escherichia coli]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20130154</link>
	<description><![CDATA[<i>Escherichia coli </i>glycogen metabolism involves regulation of the <i>glgBXCAP </i>operon expression and allosteric control of GlgC-mediated catalysis of ATP and glucose-1-phosphate (G1P) to ADP-glucose linked to glycogen biosynthesis. <i>E. coli </i>glycogen metabolism is also affected by <i>glgS</i>. Though the precise function of the protein it encodes is unknown, its deficiency causes both reduced glycogen content and enhanced levels of the GlgC negative allosteric regulator AMP. Transcriptomic analyses carried out in this work revealed that, compared with their isogenic BW25113 wild type strain, <i>glgS </i>null (&#x0394;<i>glgS</i>) mutants have increased expression of operons involved in the synthesis of type 1 fimbriae adhesins, flagella, and nucleotides. In concordance, &#x0394;<i>glgS</i> cells were hyperflagellated and hyperfimbriated, and displayed elevated swarming motility; these phenotypes were all reverted by ectopic <i>glgS</i> expression. Also, &#x0394;<i>glgS</i> cells accumulated high colanic acid content, and displayed increased ability to form biofilms on polysterene surfaces. F-driven conjugation based large-scale interaction studies of <i>glgS</i> with all the nonessential genes of <i>E. coli</i> showed that deletion of purine biosynthesis genes complement the glycogen-deficient, high motility and high biofilm content phenotypes of &#x0394;<i>glgS</i> cells. Overall, these data indicate that glycogen deficiency in &#x0394;<i>glgS</i> cells can be ascribed to high flagellar propulsion, and high exopolysaccharide and purine nucleotides biosynthetic activites competing with GlgC for the same ATP and G1P pools. Supporting this proposal, glycogen-less &#x0394;<i>glgC </i>cells displayed an elevated swarming motility, and accumulated high levels of colanic acid and biofilm. Furthermore, <i>glgC</i> over-expression reverted the glycogen-deficient, high swarming motility, high colanic acid and high biofilm content phenotypes of &#x0394;<i>glgS</i> cells. Because GlgS emerges now as a major determinant of <i>E. coli </i>surface composition, and because its effect on glycogen metabolism appears to be only indirect, we propose to rename it as ScoR for Surface Composition Regulator.]]></description>
	<dc:creator>M Rahimpour, M Montero, G Almagro, A M Viale, A Sevilla, M C&#x00E1;novas, F Jos&#x00E9; Mu&#x00F1;oz, E Baroja-Fern&#x00E1;ndez, A Bahaji, G Eydallin, H Dose, R Takeuchi, H Mori, J Pozueta-Romero</dc:creator>
	<dc:date>2013-03-28T16:39:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20130154</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2013-03-28</prism:publicationDate>
	<prism:section>BJ Gene</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121666">
	<title><![CDATA[Sp sites contribute to basal and inducible expression of the human TNF{alpha}-Inducible Protein 3-Interacting Protein 1 (TNIP1) promoter]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20121666</link>
	<description><![CDATA[TNF&#x03B1;-induced protein 3-interacting protein 1 (TNIP1) is a corepressor of RAR and PPAR. Additionally, it can reduce signaling stemming from cell membrane receptors such as those for TNF&#x03B1; and EGF. Consequently, it influences a variety of receptor-mediated events as diverse as transcription, programmed cell death, and cell cycling. Thus, changes in TNIP1 expression levels are likely to impact multiple important biological endpoints. TNIP1 expression level changes have been linked to psoriasis and systemic sclerosis. As such, it is crucial to determine what controls its expression levels starting with constitutive control of its promoter. Our analysis of the TNIP1 promoter revealed multiple transcription start sites in its GC-rich proximal regions along with two transcriptionally active specificity protein (Sp) sites, responsive to both Sp1 and Sp3. EMSA and ChIP demonstrated physical binding between Sp1, Sp3 at these sites. Decrease of Sp1 protein levels via siRNA or diminished Sp1 DNA binding by mithramycin decreased TNIP1 mRNA levels. This Sp-binding, GC-rich region of the TNIP1 promoter also participates in transcriptional activation by ligand-bound RAR. Together these results demonstrate newly identified regulators of TNIP1 expression and suggest possible transcription factor targets which in turn control TNIP1-related biological endpoints ranging from apoptosis to inflammatory diseases.]]></description>
	<dc:creator>P C Encarnacao, V P Ramirez, C Zhang, B J Aneskievich</dc:creator>
	<dc:date>2013-03-07T11:29:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20121666</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2013-03-07</prism:publicationDate>
	<prism:section>BJ Gene</prism:section>
</item>


</rdf:RDF>
